GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biomark Diagnostics Inc (OTCPK:BMKDF) » Definitions » ROA %

Biomark Diagnostics (Biomark Diagnostics) ROA %

: -164.56% (As of Dec. 2023)
View and export this data going back to 2015. Start your Free Trial

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Biomark Diagnostics's annualized Net Income for the quarter that ended in Dec. 2023 was $-1.21 Mil. Biomark Diagnostics's average Total Assets over the quarter that ended in Dec. 2023 was $0.74 Mil. Therefore, Biomark Diagnostics's annualized ROA % for the quarter that ended in Dec. 2023 was -164.56%.

The historical rank and industry rank for Biomark Diagnostics's ROA % or its related term are showing as below:

BMKDF' s ROA % Range Over the Past 10 Years
Min: -1932.43   Med: -1062.88   Max: -119.92
Current: -177.97

During the past 10 years, Biomark Diagnostics's highest ROA % was -119.92%. The lowest was -1932.43%. And the median was -1062.88%.

BMKDF's ROA % is ranked worse than
97.06% of 238 companies
in the Medical Diagnostics & Research industry
Industry Median: -5.85 vs BMKDF: -177.97

Biomark Diagnostics ROA % Historical Data

The historical data trend for Biomark Diagnostics's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomark Diagnostics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
ROA %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,236.36 -361.00 -143.33 -119.52 -158.54

Biomark Diagnostics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROA % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -164.89 -247.55 -233.55 -122.65 -164.56

Competitive Comparison

For the Diagnostics & Research subindustry, Biomark Diagnostics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomark Diagnostics ROA % Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Biomark Diagnostics's ROA % distribution charts can be found below:

* The bar in red indicates where Biomark Diagnostics's ROA % falls into.



Biomark Diagnostics ROA % Calculation

Biomark Diagnostics's annualized ROA % for the fiscal year that ended in Mar. 2023 is calculated as:

ROA %=Net Income (A: Mar. 2023 )/( (Total Assets (A: Mar. 2022 )+Total Assets (A: Mar. 2023 ))/ count )
=-1.346/( (1.163+0.535)/ 2 )
=-1.346/0.849
=-158.54 %

Biomark Diagnostics's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-1.212/( (0.467+1.006)/ 2 )
=-1.212/0.7365
=-164.56 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Biomark Diagnostics  (OTCPK:BMKDF) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-1.212/0.7365
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-1.212 / 0.124)*(0.124 / 0.7365)
=Net Margin %*Asset Turnover
=-977.42 %*0.1684
=-164.56 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Biomark Diagnostics ROA % Related Terms

Thank you for viewing the detailed overview of Biomark Diagnostics's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomark Diagnostics (Biomark Diagnostics) Business Description

Traded in Other Exchanges
Address
130 - 3851 Shell Road, Richmond, BC, CAN, V6X 2W2
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early treatment for cancer. Its research and development are focused on the role that metabolomics plays in early cancer detection. It is currently focused on bringing its liquid biopsy-based cancer diagnostic tests and detection solution to commercialization.

Biomark Diagnostics (Biomark Diagnostics) Headlines

No Headlines